Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Dana-Farber Cancer Institute
- Study ID
- NCT05265429
- Status
- Recruiting
Conditions
- NUT Carcinoma
- Non Small Cell Lung Cancer
- Small Cell Lung Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 15 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Data and Specimen Collection — GENETIC* Provide research team access to relevant medical records * Answer two (2) short questionnaires at time of consent * Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample * Consider consenting to other optional parts of the research such as: * Providing additional blood or tissue samples in the future (optional) * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)
Study Details
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
Key Dates
- Start date
- Jan 1, 2023
- Status verified
- Oct 2025
- Primary completion
- Aug 1, 2027
- Completion
- Aug 1, 2027
Study Design
- Enrollment
- 500 participants (estimated)
Arms
- Arm: Data/Biospecimen CollectionTumor and saliva specimens from participants with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) diagnosed at age 45 or younger
Primary Outcome Measure
Repository of specimens and data [ Time Frame: 5 years or study closure ]
Central Contacts
- Pasi A Janne, MD, PhD617-632-6036
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02115 | Daniel Costa, MD PhD 617-667-9236 Daniel Costa, MD PhD (PRINCIPAL_INVESTIGATOR) |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Pasi A Janne, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | Pasi A Janne, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Jessica Lin, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
By condition
By specialty
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067PHASE1/PHASE2 · Recruiting · Simcha IL-18, Inc. · Scottsdale, Arizona
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)PHASE3 · Recruiting · AbbVie · Birmingham, Alabama